Curative Effect Study of Endostatin Combined With Chemoradiotherapy to Non-small-cell Lung Cancer

Inclusion Criteria: * 18 years of age * untreated pathologically confirmed inoperable stage IIIA or IIIB NSCLC * weight loss of less than 10% in the past 6 months * performance status (PS) of 0 to 1 * forced vital capacity in 1 second (FEV1) higher than 0.8 L * measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST). * absolute neutrophil count (ANC) of ≥ 1500/μL * hemoglobin ≥ 10 mg/dL * platelet ≥ 100,000/μL * serum creatinine ≤ 1.25 times of upper limit of normal (ULN) * calculated creatinine clearance (CrCl) of ≥ 60 ml/min * bilirubin 1.5×ULN * AST and ALT less than 2.5×ULN * alkaline phosphatase less than 5×ULN. Exclusion Criteria: * active infection * history of significant cardiac disease (unstable angina, congestive heart failure, myocardial infarction within the previous 6 months, ventricular arrhythmias) * malnutrition (loss of ≥ 20% of the original body weight) * sensor or motor neuropathy \> grade I * second primary malignancy, except for non-melanoma skin cancer * psychiatric illness or social situation that would preclude study compliance * pregnant or lactating women * preexisting bleeding diatheses or coagulopathy * Prior chemotherapy,chest irradiation therapy, or therapy directed at the epidermal growth factor receptor pathway